Formulated PSTA Injection Versus PATA Alone in the Management of Macular Edema Secondary to Non-ischemic Retinal Vein Occlusions
Not Applicable
Completed
- Conditions
- Macula Edema
- Interventions
- Registration Number
- NCT05385562
- Lead Sponsor
- Al-Azhar University
- Brief Summary
The aim of this study is to compare formulated Posterior Subtenon Triamcinolone acetonide (PSTA) injection versus Posterior Subtenon Triamcinolone acetonide alone in the management of macular edema secondary to non-ischemic retinal vein occlusions, either central or branch.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 78
Inclusion Criteria
- Diminution vision due to macular edema secondary to non-ischemic retinal vein occlusions, either central or branch, as evidenced by clinical and angiographic evaluation
- CMT ≥ 250 µ.
- Willing to participate in the study
Exclusion Criteria
- Unwilling to participate in the study.
- Ischemic RVO
- Prior laser treatment
- Glaucoma/Ocular Hypertension
- Cataract which lead to difficulty in the evaluation of macula
- Vitreous hemorrhage
- Macular ischemia
- Iris neovascularisation
- patients with intravitreal injection of anti VEGFs, steroid, or any intraocular surgery 3 months prior to the inclusion.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Formulated Posterior Sub Tenon Triamcinolone Triamcinolone Acetonide and sodium hyaluronate and chondroitin sulfate - Posterior Sub Tenon Triamcinolone alone Triamcinolone Acetonide alone -
- Primary Outcome Measures
Name Time Method Best-corrected visual acuity (BCVA) at 6th month will be measured with the Snellen chart
central macular thickness ( CMT) at 6th month CMT will be measured with OCT
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does sodium hyaluronate and chondroitin sulfate in PSTA enhance corticosteroid efficacy for non-ischemic RVO macular edema?
What comparative effectiveness data exist for PSTA versus anti-VEGF therapies in treating central/branch retinal vein occlusion edema?
Which inflammatory biomarkers correlate with response to posterior subtenon triamcinolone formulations in RVO-induced macular edema?
What are the long-term safety profiles of posterior subtenon corticosteroid injections in non-ischemic RVO patients?
How do viscoelastic agents in PSTA formulations influence drug retention and intraocular pressure in retinal vein occlusion management?
Trial Locations
- Locations (1)
Ehab tharwat
🇪🇬Damieta, New Damietta, Egypt